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1. Introduction 
Exosomes represent a distinct class of membrane nanovesicles of endocytic origin that are 
released to the extracellular microenvironment from diverse cell types under both 
physiological and pathological conditions. Remarkable roles of exosomes have been 
revealed in intercellular communication, immune regulation, infection, aging and cancer. 
Exosomes carry and transfer proteins, nucleic acids and lipids, and are ubiquitous in most 
biofluids, such as urine, plasma, cerebrospinal fluid, etc. Membrane vesicles secreted by the 
epithelial cells of the urinary tract hold the promise to be an excellent source of disease 
relevant cargo proteins. In clinical proteomics urine is one of the most attractive biofluids as 
it can be obtained non-invasively, in large quantities and is relatively stable. Current 
isolation methods however are not sufficiently proficient to produce urinary exosomes 
(UEs) at a purity grade and with reproducibility suitable for downstream LC-MS based 
quantitative proteomics applications. Consequently urinary exosome based protein 
biomarker research today exclusively relies on targeted protein studies (Table 1). 
This chapter describes the current state-of-the-art in exosome research in general and 
urinary exosomes in particular with a special focus on the potential of UEs in protein 
biomarker discovery. Recently we have developed an improved isolation/purification 
method based on double-cushion sucrose/D2O ultracentrifugation (Raj et al., 2011b). The 
method relies on the solubilization of the major impurities associated with UEs in a carefully 
selected buffer solution. The new method separates exosomes from the heavier membrane 
fragments and/or vesicles more efficiently than current protocols and is compatible with 
LC-MS-based quantitative proteomics workflow. 
2. Cell-derived exosomes: Biogenesis, composition and biological role 
Cells rely on two basic mechanisms for active, vesicle-mediated macromolecular transport 
through the cellular plasma membrane: exocytosis and endocytosis (Figure 1). Both make 
use of membrane vesicles for the packaging and trafficking of molecules. While endocytosis 
is the process in which the extracellular substances enter into a cell without directly passing 
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through the cell membrane, exocytosis is the primary means of cellular secretion. During 
both constitutive and regulated exocytosis the secretory-vesicles dock and/or fuse with the 
plasma membrane. Endocytic pathway (EP), which is primarily responsible for the uptake, 
trafficking and sorting of internalized proteins has a role in vesicle secretion too (Thery et 
al., 2002). In the EP, transmembrane proteins are sorted into lumenal vesicles of 
multivesicular bodies (MVBs). MVBs can have different destinies: they can fuse or mature 
with lysosomes where the degradation of their protein cargo takes place, or can fuse with 
the cell membrane to secrete the intraluminal vesicles (ILVs) into the extracellular space. 
These extracellularly released ILVs are called exosomes (Gruenberg et al., 2004, Keller et al., 
2006). During this process, the second inward budding of the endosome membrane results 
in a positive orientation of the ILVs lipid membrane. Thus when the ILVs are released to the 
extracellular environment, they have the same orientation as the cell membrane and have 
been shown to display many of the surface markers from their cell of origin (Thery et al., 
2002). The sorting process of membrane proteins during ILV formation is considered to be 
an active process and thus, exosomal surface proteins seem not to be a plain one-to-one 
representation of the surface markers for the cell of origin. 
While the regulation of endocytic cargo sorting and its delivery to lysosomes have been 
extensively studied (Williams et al., 2007) relatively less is known about the factors which 
regulate the formation, the release and the cargo sorting into vesicles destined to be 
exosomes. The involvement of ubiquitinization and ESCRT (endosomal sorting complex 
required for transport) protein complexes have been shown by different groups (Gan et al., 
2011, Shen et al., 2011). Though, ESCRT-independent mechanisms by means of ceramide-
mediated budding of exosomes into ILVs within the MVBs have also been identified (Marsh 
et al., 2008, Trajkovic et al., 2008). Further evidence of ESCRT-independent pathway of ILV 
formation has come from studying the protein Pmel17, a main component of the c fibrils of 
pre-melanosomes, which is targeted to intraluminal vesicles of MVBs independently of 
ubiquitination, ESCRT0 and ESCRTI (Raposo et al., 2001). The most recent model on the 
formation of ILVs combines the lipid-driven membrane deformation theory with the 
ESCRT-regulated sorting mechanism (Babst, 2011). 
Microvesicles (MVs) are generated by the outward budding and fission of membrane 
vesicles from the cell surface (Fig. 1) (Lee et al., 2011). MVs (100–1000 nm) are generally 
bigger in size than exosomes (30-100 nm). Yet due to the analytical difficulties in 
distinguishing between exosomes and MVs, which are also shed by normal and diseased 
cells, they are often grouped together. 
Many mammalian cells like dendritic, mast, epithelial, neural, stem and hematopoietic cells, 
reticulocytes, astrocytes, adipocytes, and tumor cells have been reported to release exosomes 
(Denzer et al., 2000, van Niel et al., 2006). Exosomes purified from the cell culture 
supernatants are usually heterogeneous in size and contain functional mRNA translatable to 
proteins, mature microRNAs, lipids and proteins. Proteins of exosomes have been analyzed 
both by proteomics and targeted immunochemical methods, like Western-blot, FACS with 
immunolabeling, and immunoelectron microscopy. Protein composition analysis of exosomes 
shows a rather limited sub-cellular localization for the exosomal proteins. In fact, usually the 
preparations of exosomes are mostly enriched in cytosolic and membrane proteins and 
contain less proteins of nuclear, mitochondrial, endoplasmic-reticulum or Golgi-apparatus 
origin. Secondly, exosomes express a common set of proteins. These are structural 
components and proteins with a role in exosome biogenesis and trafficking. Cell type  
specific components which presumably reflect the biological function of the parent cell on  
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Fig. 1. Schematic representation of extracellular vesicles biogenesis. The formation, release 
and cargo sorting into vesicles destined to be exosomes may involve: i) ESCRT dependent 
pathway – involving the ubiquitination and ESCRT protein complexes and ii) ESCRT –
independent pathway – like ceramide mediated budding. Microvesicles, membrane 
particles and exosome like vesicles are secreted by outward budding or fission from the cell 
surface. 
the other hand could also be identified in exosome preparations (van Niel et al., 2006). 
Protein contents of exosomes from different cells have been mapped by proteomics and the 
most of the data obtained has been catalogued in Exocarta database (Mathivanan et al., 
2009). 
Despite their role in immune system modulation (Li et al., 2006), the biological role of 
exosome secretion remained largely elusive until recent years when Lötvall’s group 
demonstrated that exosomes can transfer genetic information from one cell to another 
(Valadi et al., 2007, Taylor, 2010). Since then several mechanisms have been proposed to 
describe exosome-cell interactions: (i) cellular binding via conventional receptor–ligand 
interactions, similar to cell–cell communication. (ii) attaching/fusing with target cell 
membrane and (iii) internalization by recipient cells by endocytosis in a transcytotic manner. 
Besides the physiological roles of exosomes to remove the unwanted cellular debris, recent 
findings uncover an entirely new and exciting modes of cell–cell communication and 
paracrine signalling mediated by exosomes (Thery et al., 2002, Camussi et al., 2011). 
Emerging data shows their involvement in different diseases including inflammation, renal 
diseases, Alzheimer diseases, aging, bacterial and viral infections, allergies and cancer. 
Using different sources of tumor-derived exosomes, several groups claim that exosomes can 
prevent tumor development, induce tumor specific immunity, and provide a possible 
strategy for therapeutic tumor vaccination reviewed by van Niel et al. (van Niel et al., 2006). 
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3. Urinary exosomes 
3.1 mRNA, miRNA and protein biomarkers in urinary exosomes 
Urinary exosomes originate from those ILVs that are shed into the urinary space by the 
fusion of the outer membrane of MVBs with the apical plasma membrane of cells lining 
the urinary tract, including glomerular podocytes, renal tubule cells, and bladder. The 
number, and the physical, chemical and biological properties of UEs may change over 
time in association with disorders that affect the urinary system. Respect to the total urine 
sample, UEs result in a remarkable enrichment of low-abundance biomolecules with 
potentially high diagnostic value regarding the physiological and pathological state of the 
renal system. Therefore, it is not surprising that there is a great interest in the use of UEs 
as a novel biomarker source for early disease detection, classification, prediction severity, 
outcome and response to treatment. Since the first publication on proteomic profiling of 
UEs by the group of Knepper (Pisitkun et al., 2004), an increasing number of articles with 
keywords “exosome and urine” are to be found in the PubMed database. The principal 
aim of urinary exosome research today is to discover mRNA, microRNA and protein 
biomarkers. 
 
 
AKI - acute kidney injury 
FSGS - focal segmental glomerulosclerosis 
BC - bladder cancer 
PC - prostate cancer 
I/R - renal ischemia/reperfusion 
GKD - glomural kidney disease 
NSCL – non-small cell lung cancer 
Table 1. Different isolation/purification, protein separation, identification and quantitation 
methods used in urinary exosome related targeted protein biomarker studies. 
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mRNA transcripts encoding specific genes from various regions of the nephron, the 
collecting duct, the prostate and the bladder have been isolated from urinary exosome 
preparations (Miranda et al., 2010, Keller et al., 2011). Interestingly, RNA of UEs was found 
to be protected from RNase degradation which may suggest a functional role for the nucleic 
acids present in exosome (Keller et al., 2011). In the mRNA sample isolated from the urinary 
exosomes of prostate cancer patients PCA-3 and TMPRSS2:ERG, two known prostate cancer 
related biomarkers were detected (Nilsson et al., 2009). Urinary exosomes seem to be 
particularly rich in miRNAs too. The use of miRNA as diagnostic biomarkers in exosome 
research is an emerging field due to important potential advantages over standard mRNA 
(Li et al., 2010). 
There are over a thousand proteins identified from UE preparations published in the 
Exocarta (Mathivanan et al., 2009) and the Urinary Exosome Protein Database (Pisitkun et 
al., 2004) including the six exosome markers commonly used in exosome research (Alix, 
Tsg101, CD63, CD9, CD81, HSP70). Proteins of UEs show a different profile from that of 
total urinary proteins but with a high degree of overlap. UEs are enriched in membrane and 
cytosolic cargo proteins from the different epithelial cells lining the urinary tract (Pisitkun et 
al., 2004, Gonzales et al., 2009). For clinical biomarker discovery, LC-MS based large-scale 
quantitative proteomic analysis would be the method of choice. However, at the urinary 
exosome level it is still a daunting task (Gonzales et al., 2008, Mitchell et al., 2009, Keller et 
al., 2011). Therefore, protein quantitation and expression analysis has mainly been 
performed by targeted studies like antibody-based Western blot analysis (Table 1). For this 
reason only a few protein biomarker candidates have so far been identified in UEs. 
3.2 Isolation and purification 
Protocols for collection, storage and processing of human urine for exosome isolation and 
protein characterization have recently been published (Zhou et al., 2006b). Concerning the 
isolation of UEs, current methods rely on ultracentrifugation or filtration, or the 
combination of these two. The majority of the studies use a two-step differential 
centrifugation protocol developed by Pisitkun et al (Pisitkun et al., 2004). The initial step is a 
low velocity sequential centrifugation which serves to remove cells and cellular debris 
(urinary sediment) from urine, leaving the exosomes in the supernatant. The second step is 
the ultracentrifugation for 1h to overnight of the supernatant at 100,000-200,000g velocity to 
sediment exosomes. The major short comings of this process are the high level of 
contamination from uromodulin (see later) and the lack of separation of exosomes from the 
other MVs and membrane particles. 
To obtain higher purity grade UEs, the crude preparation obtained by the two-step 
differential centrifugation method can be further processed using the sucrose gradient or 
the sucrose cushion centrifugation. Sucrose gradient centrifugation can be performed on 
linear or step gradients typically using sucrose concentrations between 2.0 M – 0.25 M 
(Keller et al., 2007, Hogan et al., 2009, Simpson et al., 2009, Mathivanan et al., 2010). 
Instead of gradient, a small density cushion typically composed of 30% sucrose in 
deuterium oxide (D2O), can also be employed for the purification of UEs (Mitchell et al., 
2009, Simpson et al., 2009, Welton et al., 2010). In the sucrose cushion, formation of a mini 
density gradient takes place in the range of 1.10-1.18 g/cm3. This range was shown to be 
suitable to enrich and purify exosomes preventing vesicle aggregation that pelleting could 
cause. Sucrose gradient and cushion centrifugations thus allow a better separation of 
exosomes from the vesicles of different densities respect to the differential centrifugation 
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method, however it does not seem to eliminate the problem of the co-purifying 
uromodulin (Hogan et al., 2009). 
Filtration-based protocols generally use polyether sulfone nano-membranes in a spin 
concentrator to isolate urinary exosomes (Cheruvanky et al., 2007). The method is simple, 
fast and is capable to isolate UEs from small volumes of urine (0.5–10 mL). Therefore it is 
very promising, especially for mRNA and miRNA based exosome biomarker research. 
Drawbacks of this method for protein biomarker research are the low yield and the high 
level of contamination caused by urinary proteins binding to the filter. To overcome this, 
recently a low protein binding membrane (hydrophilized polyvinylidene difluoride) has 
been used to isolate urinary exosomes (Merchant et al., 2010). 
3.3 The uromodulin problem 
Current methods are characterized by a high and variable level of uromodulin contamination 
(Hogan et al., 2009, Fernandez-Llama et al., 2010, Rood et al., 2010). Uromodulin, also referred 
to as Tamm–Horsfall glycoprotein, is a major glycoprotein produced by kidney cells. 
Uromodulin assembles into intracellular filaments in urine (Porter et al., 1955, Schaeffer et al., 
2009). The filaments have an average width and length of 100 Ǻ and 2.5 µm, respectively and 
tend to form a three-dimensional matrix with pores as shown by electron microscopy (Porter 
et al., 1955). This filament network traps exosomes and prevents their efficient isolation and 
purification by traditional methods. The uromodulin problem is one of the bottle neck of UE 
protein research because it considerably reduces sample yield and reproducibility (Fernandez-
Llama et al., 2010). In order to facilitate the removal of high molecular weight aggregates 
recently, dithiothreitol (DTT) was applied to reduce the intermolecular disulfide bonds of 
uromodulin (Pisitkun et al., 2004, Fernandez-Llama et al., 2010). Treatment with DTT result in 
a higher yield of urinary exosomes. Notwithstanding it does not solve the problem efficiently. 
For this reason, urinary exosome samples prepared by the current methods are far from being 
ideal for quantitative proteomic analysis. 
4. Interfacing urinary exosome isolation/purification and lysis with 
quantitative proteomics for protein biomarker research 
Biomarkers support the diagnosis and medical management of various disorders. The 
remarkable progress made in proteomic technologies in the past decade have enabled 
researchers to consider designing studies to identify diagnostic and therapeutic biomarkers 
by analyzing complex proteome samples using unbiased mass spectrometry based methods. 
In urinary exosome research this has been hampered by the high and variable concentration 
of uromodulin causing low sample quantity, quality and low reproducibility. To meet the 
need of a global protein biomarker discovery platform we have set-up new protocols for the 
isolation/purification and also for the lysis and subsequent solubilization of membrane 
proteins. Paragraph 4.1 describes a novel urinary exosome preparation called double-
cushion ultracentrifugation method and paragraph 4.2 shows its compatibility with 
downstream analysis. 
We have employed a multiplex quantitative proteomics method, iTRAQ (isobaric Tagging 
for Relative and Absolute protein Quantification), in conjunction with multidimensional 
chromatography, followed by tandem mass spectrometry (MS/MS), to measure relative 
differences in the protein composition of urinary exosome samples (Figure 2). The aim of 
this work was to compare the protein content of UEs obtained by single- and double- 
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Fig. 2. Scheme of the MudPIT based 4-plex iTRAQ quantitative analysis comparing the 
double-cushion ultracentrifugation method with that of single-cushion. 
cushion ultracentrifugation methods. Simultaneously, we compared samples obtained from 
a single person with a pool of healthy volunteers divided into two age groups (25-50 years 
and 50-70 years) in order to study feasibility of analysis of single patient versus pooled 
samples in the discovery phase of protein biomarker research. 
4.1 A novel isolation/purification method based on uromodulin solubilization and 
double-cushion ultracentrifugation 
The urinary exosome isolation/purification method which we have recently developed (Raj 
et al., 2011b) employs a double-cushion ultracentrifugation step performed in a carefully 
chosen buffer solution. Respect to other ultracentrifugation based methods which generally 
use a PBS buffer (150 mM NaCl at pH 7.2) the novel method employs a solubilising buffer 
composed of 20 mM Tris at pH 8.6. We have found that Tris buffer efficiently solubilizes 
uromodulin aggregates, keeps uromodulin in solution and does not lyses exosomes. This is 
in accordance with a previous in vitro study on uromodulin solubility which underlines the 
importance of alkaline pH, low sodium and calcium concentrations and sample dilution to 
prevent the formation of uromodulin aggregates (Kobayashi et al., 2001). After solubilizing 
the pellet obtained in the differential ultracentrifugation step, double-cushion 
ultracentrifugation is performed. The double-cushion is made of sucrose 1 M and sucrose 2 
M prepared in 20 mM Tris pH 8.6 in D2O and subsequently under layered below the sample 
in the centrifuge tube. This step was found to considerably improve the separation of 
exosomes from the heavier vesicles and/or membrane fragments. 
4.2 Analysis of urinary vesicles at the various steps of isolation/purification 
Exosomes were purified from pooled urine samples of ten healthy donors and separated on 
4-12% gradient polyacrylamide gel then stained with colloidal Coomassie blue. SDS-PAGE 
analysis at the various phases of the isolation/purification process is shown in Figure 3. 
Total urinary protein profiles before (Figure 3.A, Lane 1) and after exosome depletion 
(Figure 3.A, Lane 2) do not markedly differ from each other and show the typical pattern of  
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Fig. 3. SDS PAGE analyses A) at the different stages of urinary exosome 
isolation/purification through the double-cushion (lanes 1-7) and the single-cushion (lane 9) 
methods and, B) of the 1 M and 2 M sucrose fractions obtained after the double-cushion 
ultracentrifugation method (major proteins identified by in-gel digestion proteomics are 
indicated next to the band). Lanes in Figure A as follow: 1- Total urine; 2- Exosome depleted 
urine; 3- Crude exosome fraction after differential centrifugation; 4- 15,000g pellet;  
5- 15,000g supernatant; 6- Purified exosomes (1 M sucrose fraction); 7- 2 M sucrose fraction; 
M- Protein molecular weight markers (kDa); 9- Urinary exosomes prepared by the single 
sucrose/D2O cushion method. Lanes in Figure B are as follow: 1- 1 M sucrose fraction and  
2- 2 M sucrose fraction and M- Protein molecular weight markers (kDa). 
the major urinary proteins, like albumin, various IgG chains, uromodulin etc. After the two-
step differential centrifugation the crude exosome pellet (Figure 3.A, lane 3) still contains a 
considerable amount of contaminating urinary proteins and in particular uromodulin at 85 
kDa. These are in part removed after the solubilization step by low-speed centrifugation 
(Figure 3.A, lane 4-5) and, in part by the double-cushion ultracentrifugation. The later yields 
two fractions: the 1 M sucrose fraction which contains the exosome vesicles (Figure 3.A, lane 
6) and the 2 M fraction which contains vesicles heavier than exosomes (Figure 3.A, lane 7). 
The efficiency of the uromodulin removal by the double-cushion sucrose ultracentrifugation 
methods can be appreciated by comparing the 1 M fraction (Figure 3.A, lane 6) with the 
crude exosome fraction (Figure 3.A, lane 3) and with the exosomes purified by the single-
cushion method (Figure 3.A, lane 9). In Figure 3.B SDS-PAGE image of the two vesicle 
containing fractions, 1 M (lane 1) and 2 M (lane 2) are shown together with the major 
proteins identified in the gel bands. It is of note that not only the protein pattern but also the 
proteins identified in the major SDS-PAGE bands were found to be different, indicating the 
presence of two different types of vesicles in the two fractions. Semenogelin 1 and 
semenogelin 2 and olfactomedin for example have previously been identified in 
prostasomes, i.e. the secretory particles in human seminal fluid (Utleg et al., 2003). Therefore 
it is plausible to presume that the 2 M sucrose fraction contains heavier vesicles, like urinary 
secreted prostasomes. 
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Western blot analysis was performed to monitor the enrichment in exosomes and the 
reproducibility of sample preparation by the double-cushion ultracentrifugation. Exosomal 
proteins were separated on 4-12% gradient SDS-PAGE and electro blotted to PVDF membrane. 
Blots were probed with antibodies against two known exosome markers Alix and TSG101, 
together with NKCC2 a renal sodium transporter known to be present in urinary exosomes 
(Figure 4.). The enrichment of exosomes is excellent in the samples prepared by the double-
cushion (Figure 4., lane 4-6) respect to the starting and exosome depleted urine samples 
(Figure 4., lane 2-3) and also to the sample prepared by the differential centrifugation method 
(Figure 4., lane 1). Importantly a very high degree of reproducibility was achieved in three 
independent urinary exosome preparations (Figure 4., lanes 4-6). 
 
 
Fig. 4. Western blot analysis of urinary exosomes prepared by two different methods. Lane 
1- Exosome purified by differential centrifugation; Lane 2- Total urine; Lane 3- Exosome 
depleted urine; Lane 4-6 – Exosomes purified in three independent experiments from 
pooled urine samples of ten healthy volunteers by the double-cushion method. 
Exosome-like vesicles isolated from culture supernatant are limited by a lipid bilayer and in 
literature often described as saucer- or cup-shaped particles. Urinary exosomes isolated by 
the double-cushion ultracentrifugation method have a similar morphology as single cell line 
derived exosomes. The transmission electron microscopy (TEM) image shows (Figure 5) that 
diameters of the vesicles purified in the 1 M fraction are between 30 and 80 nm. 
Interestingly, the shape of the exosomes appeared to be nearly spherical with only a few 
elongated or cup-shaped specimens. After the double-cushion ultracentrifugation the 
sample is basically free from the long uromodulin filaments known to contaminate UEs 
prepared by traditional methods. 
 
 
Fig. 5. Transmission electron microscopy image of urinary exosomes isolated and purified 
by the double-cushion ultracentrifugation method (1 M fraction). The image shows the 
typical morphology and size distribution of the vesicles. Frame shows the enlarged image 
(central) and the arrow shows a single vesicle enlarged on the right image. 
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5. Quantitative proteomics of urinary exosomes for protein biomarker 
discovery 
Recently, we have developed protocols for lysis, protein extraction and in-solution digestion 
of UEs for MudPIT application to quantitative proteomics (Raj et al., 2011a). For the 
solubilization of exosomal membrane proteins the use of an acid cleavable detergent was 
found to be particularly useful. In a preliminary study four exosomal protein samples were 
prepared in parallel (Table 2) according to single- (sample 4) and double-cushion protocols 
(sample 1) from a pooled urine sample of 20 healthy donors (male, age group 25-45 years). 
Effects of age (sample 2) and sample pooling (sample 3) on the protein expression were also 
monitored in the same experiment.  
 
Sample Age (years) Number of samples 
Exosome preparation 
method 
Label 
1 25-45 20 Double-cushion iTRAQ-114 
2 50-70 20 Double-cushion iTRAQ-115 
3 43 1 Double-cushion iTRAQ-116 
4 25-45 20 Single-cushion iTRAQ-117 
Table 2. Samples analysed by in-solution digestion based MudPIT proteomics and iTRAQ 
labeling. 
The 4-plex iTRAQ method (Ross et al., 2004) based on covalent labeling of the N-terminus 
and side-chain amines of peptides with four tags of varying mass was used for the protein 
quantitation (Figure 2.). 
Protein samples were denatured, reduced, alkylated, enzymatically digested by trypsin and 
then labeled according to the manufacturer’s protocol (iTRAQ reagent kit, Applied 
Biosystems). After iTRAQ labeling equal amounts of each sample (100 µg) were mixed, 
vacuum dried, detergent was acid cleaved and the resulting sample was desalted. The 
purified sample was then separated by two-dimensional HPLC. For strong cation-exchange 
(SCX) chromatography, in the first dimension, the following conditions were used: 95% 
solvent A (20% acetonitrile, 0.05% formic acid) and 5% solvent B (20% acetonitrile, 0.05% 
formic acid, 500mM KCl) for 3 min, solvent B ramped up to 90% in 40 min and maintained 
at 100% for 7 min. 47 fractions were collected between 0-55 min. Fractions were further 
separated in the second dimension on a reversed phase monolithic nano column using the 
following conditions: 95% solvent C (2% acetonitrile, 0.1% formic acid) and 5% solvent D 
(98% acetonitrile, 0.1% formic acid) for 5 min, ramp to 50% solvent D in 90 min and in 6 sec 
to 98% solvent D for 10 min. Eluting peptides were analyzed online by a QTOF type of 
tandem mass spectrometer (Qstar Elite) in an information dependent acquisition mode 
which facilitates both the protein identification and the multiplex quantitative analysis of 
the four samples. Tandem mass spectra were extracted and peak lists were generated by 
Analyst QS 2.0 software using the default parameters. Peak lists containing all acquired 
MS/MS spectra were searched against SwissProt 2010_09 (519348 sequences) database using 
Mascot Server (version 2.2) with trypsin specificity and allowing for up to one missed 
cleavage. iTRAQ at lysine residue and the N termini of the peptides and 
carbamidomethylation of cysteines were considered as fixed modifications whereas 
oxidations of methionine and iTRAQ at tyrosine residues were set as possible variable 
modifications. Mass tolerance was set to 50 ppm for precursor and to 0.1 Da for fragment 
ions, respectively. Low molecular mass reporter ions were used to relatively quantify the 
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peptides and the proteins from which they originate by Mascot iTRAQ 4-plex quantification 
method. Proteins which were quantified with a minimum of two unique peptides and 
p<0.05 significance threshold using MudPIT scoring have been considered. 
More than hundred proteins were quantified in the iTRAQ analysis. Table 3. shows the 
weighted median ratios of the first 25 proteins ranked by Mascot protein score. Expression 
level of the major proteins isolated and purified by the double-cushion method are different 
from those purified with the single-cushion protocol (Table 3., ratio 117/114). In particular, 
cytoskeletal proteins (cubulin, megalin, actin, cofillin, moesin, tubulin, etc.) seem to be less 
abundant in the sample. They may be due to heterogeneous constituents of the cytoskeleton 
filaments present in urine which co-purify with the UEs in traditional methods. On the other 
hand a marked enrichment was observed in proteins which are related to the VPS4 complex 
of ESCRT machinery (IST1, VPS4A, and VPS4B), its associated proteins (CHM2A, CHMP5,  
 
UniProt ID Protein Name Mascot 
score 
115/114 116/114 117/114 
AMPN_HUMAN Aminopeptidase 1315 0.845 1.306 0.237 
IST1_HUMAN IST1 homolog 656 1.037 0.706 0.406 
ACTB_HUMAN Actin, cytoplasmic 430 1.408 1.631 0.733 
DPEP1_HUMAN Dipeptidase 1 370 0.857 0.700 0.430 
VPS4A_HUMAN 
Vacuolar protein sorting-associated protein 
4A 
350 1.150 0.742 0.473 
CHM2A_HUMAN Charged multivesicular body protein 2a 341 1.242 1.493 0.595 
UROM_HUMAN Uromodulin 282 0.958 0.578 22.450 
CHMP5_HUMAN Charged multivesicular body protein 5 279 1.082 0.569 0.161 
RS27A_HUMAN Ubiquitin-40S ribosomal protein S27a 275 1.051 0.764 0.445 
GGT1_HUMAN Gamma-glutamyltranspeptidase 267 0.840 1.045 0.342 
NEP_HUMAN Neprilysin 258 0.897 0.995 0.381 
EZRI_HUMAN Ezrin 254 1.245 1.093 0.776 
ANX11_HUMAN Annexin A11 252 1.393 0.435 0.601 
PSCA_HUMAN Prostate stem cell antigen 231 1.415 5.214 0.345 
HSP7C_HUMAN Heat shock cognate 71 kDa protein 208 1.186 0.990 0.428 
PDC6I_HUMAN 
Programmed cell death 6-interacting 
protein 
231 1.093 0.684 0.500 
CDC42_HUMAN Cell division control protein 42 homolog 208 1.044 1.773 0.190 
VPS4B_HUMAN 
Vacuolar protein sorting-associated protein 
4B 
195 1.063 0.601 0.500 
CHM4B_HUMAN Charged multivesicular body protein 4b 181 1.308 0.923 0.559 
POTEF_HUMAN POTE ankyrin domain family member F 176 1.394 1.404 0.510 
DPP4_HUMAN Dipeptidyl peptidase 4 175 0.931 0.837 0.320 
AQP1_HUMAN Aquaporin-1 167 0.898 0.679 0.573 
THY1_HUMAN Thy-1 membrane glycoprotein 151 1.316 2.332 0.354 
MUC1_HUMAN Mucin-1 145 0.945 0.523 0.743 
PROM1_HUMAN Prominin-1 140 1.014 0.655 0.500 
Table 3. The weighted median ratios of the 25 top-ranking proteins in the MudPIT based 4-
plex iTRAQ experiment. 114, 115, 116 and 117 indicate sample-labeling by iTRAQ according 
to Table 2. 
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CHM4B) and proteins involved in the ubiquitination process (RS27A). The most abundant 
protein according to SDS-PAGE and MudPIT analyses is aminopeptidase (AMPN) known 
to reflect a periodicity in renal tubular function. Other proteins like AQP1, NEP, DPEP1 
and DPP4 also related to renal function were identified among the most abundant 
proteins. Based on statistical analysis of the data, more than a 2-fold change was 
considered to be significant. Data obtained confirms that the double-cushion method 
efficiently removes the major urinary protein contamination characteristic of the current 
purification methods (more than a 20-fold change). In different single-cushion 
preparations (data not shown) the relative protein quantities vary considerably respect to 
that of uromodulin (i.e. mean of the fold changes of all quantified proteins unless 
uromodulin/uromodulin fold change). This can be explained by the poor reproducibility 
and it causes considerable complications in protein quantification and normalization. 
Comparing the two different age-groups we analysed, no significant difference in the 
expression was found in the 25 top-ranking exosomal proteins (Table 3., ratio 115/114). 
The individual sample, on the other hand shows few characteristic differences when 
compared with the pooled samples (116/114). In our study, the expression levels of PSCA 
and THY1 and ANX11 were found to be significantly altered respect to the age-matched 
control group. For a protein biomarker discovery platform which employs urinary 
exosomes as biomarker source, it is highly advisable to use a pooled control sample with a 
high number and clinically well defined individual samples. 
6. Conclusions 
Given the non-invasive nature of urine sample collection and the evolving biological 
significance of secreted membrane vesicles, unbiased quantitative analysis of 
biomolecules isolated from urinary exosomes is a step forward in clinical biomarker 
research. Recently we have set-up a multiplex quantitative approach for the analysis of 
protein contents of purified urinary exosomes (Figure 2.). This includes protocols for i.) 
the removal of major urinary exosome contaminations, ii.) the separation of urinary 
membrane vesicles of different sizes iii.) vesicle lysis and protein solubilization and, iv) 
the quantitative proteomics based urinary exosomal biomarker research. The novel 
isolation/purification procedure efficiently removes the major urinary exosomal 
contaminations and separates exosomes from other membrane vesicles. Thus it provides a 
good basis for the development of optimized methods for protein biomarker research. 
Quantitative MudPIT analysis performed on biological, analytical and technical replicates 
shows excellent reproducibility. No significant expression difference was found among 
normal healthy subjects grouped by age. Preliminary data suggests a superior 
performance in single sample biomarker analysis design over a pooling design. All 
together, these results suggest a prolific future of urinary exosomes in clinical proteomics 
of different diseases involving the renal and urinary tract. 
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